EQUITy in Black Adult Health (EQUITA) - a Randomised Feasibility Trial of a Co-produced and Faith-placed Intervention to Increase Uptake of Breast, Cervical, Bowel, and AAA Screening in the North East of England, Leeds and Scotland

The goal of this randomised feasibility trial is to examine feasibility and acceptability of a co-produced and faith-placed intervention to increase uptake of breast, cervical, bowel, and abdominal aortic aneurysm (AAA) screening among Black communities in the North East of England, Leeds and Scotland, United Kingdom (UK).
Participants will be invited to attend a two-hour workshop at each of the three study sites and will be randomly assigned to either the intervention group or the control group.
This 24-month feasibility study will inform the development of a full-scale randomised-controlled trial co-produced for Black people that uses culturally appropriate messages that support screening for early diagnosis in this underserved group.

Start Date01 Sep 2025

Sponsor / Collaborator

University of Sunderland

[+1]

ISRCTN65120935

/ RecruitingNot ApplicableIIT

Safeguarding adults for empowerment (SAFE): a qualitative study to develop best practice for involving older people in safeguarding processes

Start Date08 Oct 2024

Sponsor / Collaborator

University of Sunderland

NCT06254963

/ CompletedNot ApplicableIIT

The Effect of 6 Weeks Supplemental Jump Training on Sand Versus Hard Surfaces on Landing Knee Valgus and Jump Performance in Adolescent Female Football Players

The aim of this study is to investigate the effect of a supplemental jump training program (added to a warm up) conducted on either sand or hard surfaces on the landing and jumping ability of young female football players. The jump training program (intervention) will be carried out twice weekly for a period of 6 weeks. Participants will be randomised (computer package will decide) into one of 2 groups (either sand training or land training). The landing ability and jumping performance of all participants will be measured both before and after the 6 week jump training intervention. It is hypothesised that supplemental training on both sand and hard surfaces will improve landing ability and jumping performance. It is also hypothesised that sand will be equally as effective as a hard surface for improving jump landing ability but may be less effective than a hard surface for improving jumping performance.

Start Date14 Feb 2024

Sponsor / Collaborator

University of Teesside

[+1]

100 Clinical Results associated with University of Sunderland

0 Patents (Medical) associated with University of Sunderland

1,609

Literatures (Medical) associated with University of Sunderland

01 Oct 2025·Currents in Pharmacy Teaching and Learning

Undergraduate pharmacy placements in the primary care clinical environment: An exploration of students' experiences of a pilot placement

Article

Author: Collins, Charlotte ; Robertshaw, Carlie ; Hardisty, Jessica ; Cope, Sarah ; Goring, Rob

OBJECTIVES:

To explore the experiences of undergraduate pharmacy students, undertaking a pilot placement in a primary healthcare setting.

METHODS:

A longitudinal placement for undergraduate pharmacy students in primary healthcare was designed in collaboration with practice management staff, doctors, nursing staff, pharmacists and academics. The placement was designed to facilitate the application of students' clinical skills and provide them with an opportunity to collect evidence of their professional development. A primary healthcare centre was identified to host the pilot longitudinal placement and pharmacy students in their third year of undergraduate study were recruited to take part. Following completion of the longitudinal placement a focus group was conducted with the students who completed the pilot to determine their experiences.

KEY FINDINGS:

Students reported that the longitudinal placement allowed them to become integrated into the primary healthcare team, apply knowledge they had gained during their academic studies and develop their clinical and decision-making skills. Students also valued the authentic interactions they had during the placement with other members of the multidisciplinary team and the opportunity to develop their professional identity.

CONCLUSIONS:

The evaluation of this pilot suggest that placements in primary healthcare could support pharmacy students to develop their physical assessment skills, clinical decision making and apply the knowledge they have gained at university in a live clinical environment.

01 Jul 2025·EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

Flexipill: A novel 3D printed flexible dose combination for hypertension with a floating element

Article

Author: Anis, Tanzeela ; Karkar, Yasir ; Elkordy, Amal Ali ; Faheem, Ahmed

Hypertension is highly prevalent worldwide, affecting approximately one in three adults. The pathophysiology of hypertension is multifactorial, which led recent guidelines to recommend the initiation of treatment with more than one antihypertensive agent. This exacerbates the existing issue of polypharmacy, particularly among geriatric patients. Polypharmacy can lead to a reduction in patient adherence to the treatment. As a result, many clinical studies have investigated using fixed-dose combinations to address this issue. These studies have demonstrated the effectiveness of a polypill in improving patient adherence. However, a polypill limits the flexibility for dose titration and personalisation of treatment. Therefore, when 3D printing was first introduced to pharmaceutical formulation, researchers recognised the potential of this technology for drug personalisation and the creation of more flexible drug combinations. Nonetheless, regulatory concerns still limit the translation of these research efforts into clinical applications that can benefit the patient. Consequently, this study seeks to bridge the existing gap by identifying a balanced approach between regulatory requirements and the concept of personalised drug combinations. The Flexipill is a flexible dose combination that does not require printing at the pharmacy level. It can be printed at a quality-controlled facility and assembled according to patient needs at the point of care. In this work, an antihypertensive Flexipill was printed, with each unit having different drug release profiles and formulation requirements. The propranolol HCl unit was printed as a floating unit to improve its solubility and bioavailability. It floated for 9 h, releasing over 90 % of the drug content. The enalapril maleate unit was formulated to avoid thermal degradation by printing at 150 °C, which is lower than its degradation temperature. Moreover, hydrochlorothiazide was formulated to provide immediate release of over 90 % of the drug within the first hour.

01 Jun 2025·JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY

Flexipill: A novel 3D printed personalised analgesic polypill with diverse targeted drug release approaches

Author: Amer, Ihsan ; Karkar, Yasir ; Elkordy, Amal Ali ; Faheem, Ahmed

In recent years, considerable attention has been directed towards three-dimensional printing (3D printing) as a promising technique for personalising medications, particularly in the development of personalised polypills.Among the various 3D printing technologies, fused deposition modeling (FDM) has gathered significant attention due to its cost-effectiveness and simplicity.Nonetheless, FDM was not without its limitations, notably the elevated printing temperatures and limited drug-loading capacities.Furthermore, personalised polypill production required the printing process to be conducted at the point of care, which encountered significant resistance from regulatory authorities for widespread application.In this study, an analgesic polypill was formulated with a novel design that allowed for post-printing customization according to individual patient needs.This polypill was composed of units containing either paracetamol, ibuprofen, or caffeine.The paracetamol component, aside from possessing taste-masking attributes, was designed to exhibit a high drug load of up to 55 % and could be printed at a comparatively lower temperature of 100 °C.The ibuprofen formulation was developed with gastroprotective properties, reducing its dissolution rate in an acidic gastric medium to less than 1 % after 24 h.Lastly, the caffeine formulation exhibited immediate release, with 84 % of the drug being released within the first 30 min.

News (Medical) associated with University of Sunderland

07 Jan 2022

·kbio.com

BAT creates biotech company KBio to accelerate development of existing plant-based technology

KBio will leverage BAT’s existing capabilities to advance its plant-based technology and existing clinical and pre-clinical pipeline Quality Assurance and Control Certification More than 20 publication on bioanalytical methods and plant-based proteins Ph.D. in Bioanalytical Chemistry from University of Kentucky BAT today announced the launch of KBio Holdings Limited (KBio) to accelerate the research, development and production of novel treatments. KBio will leverage the existing and extensive plant-based technology capabilities of BAT and Kentucky BioProcessing Inc (KBP), the existing BAT-owned US plant biologics organisation. KBio will explore new opportunities to develop its plant-based production system, which has the potential to offer greater speed, scale-up opportunity and thermostability. The new company will focus on delivering treatments for rare and infectious diseases by realising and expanding the potential of both the plant-based technology platform, as well as its existing clinical and pre-clinical vaccines and antibody pipeline. KBio will look to form innovative R&D collaborations and financing aimed at expanding its pipeline and future portfolio, with an ambition of financial self-sufficiency. Supporting the company’s future plans, a standalone operational structure for KBio is being established. This includes building a new executive leadership team led by Patrick Doyle as the Chief Executive Officer of KBio. Mr. Doyle brings more than 20 years of experience leading innovative biotech companies. Patrick Doyle, CEO at KBio, said: “I am excited by the opportunity to build on the significant accomplishments made by BAT and KBP. I am confident in the potential of KBio’s powerful plant-based platform, capabilities and emerging early-stage pipeline. To-date, the technology has demonstrated its ability to produce novel antibody and vaccine candidates with high purity at a fraction of the time and cost of current technologies. The speed and efficiency demonstrated by the KBio platform has significant potential. This could enable us to progress to clinical studies faster than industry norms, in the hope of delivering treatment solutions more quickly.” Dr. David O’Reilly, BAT’s Director of Scientific Research, said: “Science and innovation are fundamental to BAT and delivering on our purpose of building A Better Tomorrow. We recognise the potential of our innovative plant-based technology and have established KBio to maximise that potential. We are excited to see what the future holds.” Full article PATRICK DOYLE BIO Patrick Doyle brings more than 20 years of leadership experience within pharmaceutical and biotech companies to his new role as CEO of KBio. He is a proven leader with a track record of innovation, talent development, and a deep knowledge of pharmaceutical development, M&A and pathways to successful commercialisation. He most recently served as CEO of Stelexis Therapeutics in New York, a biotech company with a proprietary platform to discover and selectively target pre-cancerous stem cells. Mr. Doyle has also been responsible for multiple financings and strategic exits of biotechs of various stages of development. During his Big Pharma tenure, he led an international group of corporate development executives executing several large alliances in Asia and Japan. Patrick is originally from the UK, and has worked in the UK, Switzerland, California and more recently in New York City. He has a BSc in Pharmacology from the University of Sunderland. ABOUT KBIO KBio aims to create a new generation of biotech solutions using its plant-based platform that has demonstrated an ability to create drug candidates at a fraction of the time and cost of current platforms. The company is focused on developing novel product candidates in two core areas: 1) Antibody therapies for areas of high unmet need; and 2) Pandemic preparedness and response for future pandemics using its plant-based production system to create antibodies and vaccines in shorter timeframes than industry norms. Formed in 2021 KBio is based in the UK and is a subsidiary of BAT For more information, please visit www.kbio.com KBio Inc is a wholly owned subsidiary of KBio Holdings Limited, a BAT Group company.

Executive ChangeVaccine

100 Deals associated with University of Sunderland

100 Translational Medicine associated with University of Sunderland

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 27 Jun 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

University of Sunderland

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 27 Jun 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing